BioRestorative Therapies suspends shipments of ExoCR and BioX products for review

BioRestorative Therapies, Inc., a modestly capitalized biotech firm trading on the Nasdaq under BRTX, has put a hold on all shipments of its ExoCR and BioX biocosmeceutical products, effective as of August 7. The suspension, announced in a press release, is a result of an internal business review and regulatory assessment, but no decisions have been made about discontinuing the product lines. The company, with a market capitalization of just $5.61 million, reported $360,000 in revenue over the past year.

The company is currently scrutinizing the documentation, sourcing, and regulatory status pertaining to the ExoCR and BioX products. They have not yet determined whether sales will resume following the review. Located in Melville, New York, and incorporated in Nevada, BioRestorative Therapies' shares have seen a 81% decline year-to-date and an 85% drop over the past year, despite recent setbacks.

Investors reacted negatively to the suspension, but the stock is currently deemed undervalued according to InvestingPro's Fair Value assessment. The company has also entered into a $1 million revolving loan agreement with Bowery Group LLC, which enables them to request loans up to $1 million for general corporate purposes, with an interest rate of 12% per annum.

Additionally, Kaos Capital, an activist hedge fund, acquired a 4.9% stake in BioRestorative Therapies and is seeking board meetings to discuss potential strategic alternatives, including a possible review of strategic opportunities in artificial intelligence.